Welcome to our dedicated page for Relief Therapeutics Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Therapeutics Hldg stock.
Relief Therapeutics Holding AG (RLFTF) is a biopharmaceutical innovator developing therapies for rare metabolic, skin, and respiratory disorders through proprietary technologies including TEHCLO™ and Physiomimic™. This news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely information on RLFT-OD032 for phenylketonuria management, RLF-TD011 for epidermolysis bullosa care, and other pipeline advancements. Our curated collection features press releases, trial result announcements, and market authorization updates directly from corporate sources.
Key content categories include clinical study progress reports, intellectual property developments, partnership announcements, and financial performance updates. Bookmark this page for centralized access to verified information about therapeutic innovations addressing unmet medical needs.
Relief Therapeutics Holding AG (OTCQB: RLFTF) has announced that NRx Pharmaceuticals submitted an application to the FDA for Emergency Use Authorization (EUA) for its drug aviptadil to treat critical COVID-19 patients with respiratory failure. The EUA submission is based on a successful phase 2b/3 clinical trial in the U.S. Relief anticipates the decision from the FDA and is optimistic about the drug's potential to provide effective treatment options. The company also acknowledges NRx's recent Nasdaq listing and aims to advance aviptadil's development in Europe.
NRx Pharmaceuticals (Nasdaq: NRXP) has applied for Emergency Use Authorization (EUA) from the FDA for its drug, ZYESAMI™ (Aviptadil-acetate), aimed at treating critically ill COVID-19 patients with respiratory failure.
The study revealed a significant improvement in patient survival and reduced hospital stays compared to a placebo. Enrolled were 196 participants, and the findings support ZYESAMI™ as the first medication showing effectiveness for patients in advanced stages of COVID-19. The clinical trial had positive implications for patient recovery despite prior treatments.
Relief Therapeutics has appointed Dr. Taneli Jouhikainen as its new Chief Operating Officer, effective June 1, 2021. This newly created role aims to support the company’s transition from a clinical-stage entity to a diversified product-driven firm. Dr. Jouhikainen brings over 25 years of life sciences experience, having held significant positions in various biopharmaceutical companies. His responsibilities include overseeing product development and integration of new activities to bolster Relief’s growth strategy.
Relief Therapeutics Holding AG has announced its Annual General Meeting (AGM) to be held on June 18, 2021, due to the COVID-19 pandemic, shareholders will participate virtually. Key agenda items include the approval of the Annual Report and financial statements for 2020, discharge of the Board and Executive Committee, and proposals to increase authorized and conditional share capital. Notably, a loss of CHF 20,009,867 for 2020 was reported, with proposed limits on compensation for Board and Executive members unchanged from 2020.
Relief Therapeutics provided an update on ACER-001, a powder formulation of sodium phenylbutyrate for treating urea cycle disorders (UCDs). The company announced a Type B pre-NDA meeting with the FDA, aiming for an NDA submission in mid-2021. In Europe, Relief plans to engage with the European Medicines Agency regarding a Marketing Authorization Application later in 2021. If successful, ACER-001 could launch in both regions in 2022, targeting UCDs and Maple Syrup Urine Disease. Relief emphasizes the urgent need for better treatment options for UCD patients.
Relief Therapeutics (OTCQB: RLFTF) has expressed enthusiasm over the initiation of a pivotal clinical trial by APR Applied Pharma Research for its nasal spray targeting COVID-19. This development follows Relief's signing of a binding term sheet to acquire APR, which is set to enhance Relief's clinical pipeline with complementary late-stage candidates. The acquisition promises commercial revenues and access to established markets in Europe. Relief's lead product, RLF-100 (aviptadil), is also advancing in clinical trials aimed at treating lung injury caused by COVID-19.
Relief Therapeutics announced the signing of a binding term sheet to acquire APR Applied Pharma Research for CHF 22 million in cash and CHF 50 million in Relief shares. The acquisition is expected to diversify Relief's pipeline with both commercial and clinical-stage programs, enhancing revenue potential with APR's existing products. The deal aims for immediate earnings accretion and grants Relief access to APR's commercial infrastructure in Europe. Notably, APR's Sentinox has recently been cleared as a Class III medical device in the EU.
Relief Therapeutics announced that the first patient will be enrolled next week in a phase 2 trial for inhaled RLF-100 aimed at preventing COVID-19-related acute respiratory distress syndrome (ARDS). Conducted in Switzerland, the trial will include 80 patients and assess clinical improvement over 28 days. The company is also preparing a phase 2b/3 study for the intravenous formulation of RLF-100 and exploring further clinical development in non-COVID-19 indications. The completion of the trial is estimated between 6-12 months.
Relief Therapeutics Holding AG (OTCQB: RLFTF) has addressed disputes with partner NeuroRx, Inc. regarding the collaboration on RLF-100 (aviptadil). Key issues include NeuroRx's refusal to share clinical trial data, a claim of $4 million in unpaid invoices without valid documentation, and disputes over funding responsibilities for a new clinical trial for COVID-19 treatment. Relief believes these points may affect profit-sharing agreements outlined in their collaboration. Despite these challenges, Relief plans to take necessary actions to enforce its rights under the collaboration agreement.
Relief Therapeutics reported its 2020 financial results on April 15, 2021, highlighting a strong cash position of CHF 43.1 million, up from CHF 0.1 million in 2019. Key developments included advancement in the clinical trials for RLF-100 (aviptadil) for COVID-19 and a new collaboration for ACER-001 targeting orphan diseases. Despite a significant EBITDA loss of CHF 20.3 million, the company successfully raised CHF 58 million in equity financing throughout 2020. Looking ahead, Relief plans to expand its pipeline and pursue regulatory submissions for its lead projects.
